Article
A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Annals of palliative medicine - 1 Jul 2021
Zeng Hao, Liu Yujie, Wang Weiya, Tang Yuan, Tian Panwen, Li Weimin
Abstract excerpt
An increasing number of anaplastic lymphoma kinase (ALK) gene fusion variants have been reported with the popularity of next-generation sequencing (NGS), such as striatin gene (STRN)-ALK, EMAP like 4 (EML4)-ALK and S1 RNA binding domain 1 (SRBD1)-ALK. The clinical outcomes of non-small cell lung cancer (NSCLC) patients improved dramatically with the treatment of tyrosine kinase inhibitors (TKIs), but responses to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.